Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the first quarter ended March 31, 2006. The Company reported a net loss of $(548,771), or $(0.07) per share, compared with a net loss of $(183,547), or $(0.03) per share, in the prior year. The increased loss for such period resulted primarily from increased clinical development expenses related to IoGen™, salaries and related costs and facility expenses previously allocated to manufacturing, and consulting and other service expenses.
